Editas Medicine Stock Investor Sentiment
| EDIT Stock | USD 1.84 0.02 1.08% |
Slightly above 68% of Editas Medicine's investor base is looking to short. The analysis of the overall investor sentiment regarding Editas Medicine suggests that many traders are alarmed. Editas Medicine's investing sentiment can be driven by a variety of factors including economic data, Editas Medicine's earnings reports, geopolitical events, and overall market trends.
Comfort Level 32
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Editas Medicine's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Editas Medicine.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Editas Historical Sentiment
Although Editas Medicine's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Editas, such as negative comments on social media and news outlets, may cause fear in the market and push Editas Medicine's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Editas.
Editas |
Editas Medicine Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Editas Medicine can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Editas Medicine Historical Investor Sentiment
Investor biases related to Editas Medicine's public news can be used to forecast risks associated with an investment in Editas. The trend in average sentiment can be used to explain how an investor holding Editas can time the market purely based on public headlines and social activities around Editas Medicine. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Editas Medicine's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Editas Medicine and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Editas Medicine news discussions. The higher the estimate score, the more favorable the investor's outlook on Editas Medicine.
Far too much social signal, news, headlines, and media speculation about Editas Medicine that are available to investors today. That information is available publicly through Editas media outlets and privately through word of mouth or via Editas internal channels. However, regardless of the origin, that massive amount of Editas data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Editas Medicine news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Editas Medicine relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Editas Medicine's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Editas Medicine alpha.
Editas Medicine Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Hopfield Jessica of 45000 shares of Editas Medicine at 5.6415 subject to Rule 16b-3 | 11/29/2024 |
2 | Disposition of 541 shares by Mei Baisong of Editas Medicine at 2.0772 subject to Rule 16b-3 | 12/03/2024 |
3 | Brokerages downgrade gene editing company Editas to hold, shares slump 23 | 12/13/2024 |
4 | Editas Medicines SWOT analysis gene editing firm pivots strategy amid stock uncertainty | 12/18/2024 |
5 | Acquisition by Mei Baisong of 54000 shares of Editas Medicine at 8.72 subject to Rule 16b-3 | 12/19/2024 |
6 | Why Is Editas Medicine, Inc. Among the Top CRISPR Stocks to Invest In | 12/30/2024 |
7 | CRISPR-based Gene Editing Market Report 2025, with Company Profiles of the Top 10 Major Market Players | 01/13/2025 |
8 | Acquisition by Scadden David of 25000 shares of Editas Medicine at 9.55 subject to Rule 16b-3 | 01/15/2025 |
9 | Brokers Offer Predictions for Editas Medicine FY2025 Earnings | 01/22/2025 |
10 | Editas Medicine, Inc. Short Interest Up 7.6 percent in January - MarketBeat | 02/07/2025 |
11 | Genome Engineering Market To Reach USD 30.9 Billion by 2032, Growing at CAGR 16.7 percent Agilent Technologies, Bluebird Bio, Boehringer Ingelheim | 02/12/2025 |
12 | PTC Therapeutics Expected to Beat Earnings Estimates Can the Stock Move Higher | 02/20/2025 |
13 | Editas Medicine to Announce Fourth QuarterFull Year 2024 Financial Results and to Participate in Investor Conferences in March | 02/24/2025 |
14 | Mirum Pharmaceuticals, Inc. Reports Q4 Loss, Tops Revenue Estimates | 02/26/2025 |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.